AMED

Amedisys, Inc. (AMED) | Rumor.io

Amedisys

AMED

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AMED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 8

The Amedisys (AMED) merger was likely already priced in by the market.
The deal's outcome will have little impact on UnitedHealth (UNH) in the short term.
A blocked deal might have had a slightly positive effect on UNH in the short term.

Generated by AI

Sentiment

Of the messages about AMED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Bullish· Jun 9

Amedisys, Inc. (AMED) has broken out again, indicating the stock may still be undervalued.
Deutsche Bank has upgraded Amedisys to a Buy rating with a price target of $41, citing the company's potential for growth.
The stock has seen significant gains, with a 12.44% increase in value, making it one of the top-performing stocks among a list of 240.

Bearish· Jul 26

Amedisys, Inc. (AMED) was downgraded to neutral by Mizuho Securities.
The company's home health business may be negatively impacted by CMS proposals to change Medicare payments.
Amedisys' stock price has declined significantly, down 18% following the downgrade.

Generated by AI

Topics

Of the messages about AMED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	95.95%
Controversies	—	—	—	4.62%
Earnings	—	—	—	1.16%
Macro	—	—	—	0%
Technical Analysis	—	—	—	-1.73%

Earnings· Jul 31

Amedisys, Inc. (AMED) reported FQ2 earnings of $1.00 EPS and $411.60M in revenue, beating estimates.
The company guides FY18 EPS of $3.32-3.41, excluding non-recurring items, versus a consensus of $3.11.
Amedisys also updates FY18 revenue guidance to $1.63-1.65 billion.

Analysts· Feb 25

BMO Capital Markets upgraded Amedisys to Outperform from Market Perform and lowered the price target to $190.
Credit Suisse and Oppenheimer maintained Amedisys as Outperform but lowered the price target to $195 and $200, respectively.
Analysts at Raymond James, Royal Bank of Canada, and Truist Financial lowered their price targets for Amedisys to $200, $199, and $200, respectively.

Announcements· Aug 7

Amedisys, Inc. (AMED) has reached a settlement with the DOJ regarding a $3.3B merger with UnitedHealth (UNH).
The settlement requires divestitures and a $1.1M fine to resolve the merger challenge.
The agreement may reduce expected synergies and is seen as a catalyst for Amedisys' stock price to make a big comeback.

Generated by AI

Community

Of the messages about AMED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	4.78%
Newcomers	—	—	—	95.22%

Regulars· Oct 27

Amedisys' stock price fell 15% as Q3 earnings declined and FY22 outlook was cut, with its shares also down 10% after missing Q3 estimates and lowering FY22 guidance.
Analysts have downgraded Amedisys to a Market Perform rating from Outperform, and lowered its price target to $165.00.
Amedisys has issued quarterly earnings results, and its financial results for the three and nine months ended September 30, 2022, were announced in a Form 8-K filing.

Newcomers· Aug 5

Newcomers to the Amedisys stock are focused on its significant price drop, with one user mentioning it's the largest percentage drop since 2011.
Some users are awaiting a buy signal, with one mentioning the use of an "UltraAlgo" to beat the pump and dump game, while another is waiting to see if support will hold on the weekly chart.
Newcomers are also focused on Amedisys' debt situation and its price comparative to book value, with one user noting a debt situation that looks good, but also a high price relative to trend over the last 5 or 10 years.

Generated by AI

Also Discussed

Investors talking about AMED also mention

#	Name	Attention
1	LHCG - LHC Group, Inc.	——
2	Aethlon Medical, Inc.AEMD	0%new
3	NVRO - Nevro Corp.	——
4	Tenet Healthcare Corp.THC	0.05%new
5	InterDigital Inc.IDCC	0%new
6	ABMD - Abiomed, Inc.	——
7	Universal Health Services Inc. Class B Common StockUHS	0%0
8	Addus HomeCare CorporationADUS	0%new
9	Humana Inc.HUM	0%+0
10	The Cigna GroupCI	0%0

Amedisys, Inc.

Location

Social

What share of all stock conversation is about AMED?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 8

The Amedisys (AMED) merger was likely already priced in by the market.
The deal's outcome will have little impact on UnitedHealth (UNH) in the short term.
A blocked deal might have had a slightly positive effect on UNH in the short term.

Generated by AI

Sentiment

Of the messages about AMED that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% 0
Bearish	—	—	—	0% 0

Bullish· Jun 9

Amedisys, Inc. (AMED) has broken out again, indicating the stock may still be undervalued.
Deutsche Bank has upgraded Amedisys to a Buy rating with a price target of $41, citing the company's potential for growth.
The stock has seen significant gains, with a 12.44% increase in value, making it one of the top-performing stocks among a list of 240.

Bearish· Jul 26

Amedisys, Inc. (AMED) was downgraded to neutral by Mizuho Securities.
The company's home health business may be negatively impacted by CMS proposals to change Medicare payments.
Amedisys' stock price has declined significantly, down 18% following the downgrade.

Generated by AI

Topics

Of the messages about AMED that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	95.95%
Controversies	—	—	—	4.62%
Earnings	—	—	—	1.16%
Macro	—	—	—	0%
Technical Analysis	—	—	—	-1.73%

Earnings· Jul 31

Amedisys, Inc. (AMED) reported FQ2 earnings of $1.00 EPS and $411.60M in revenue, beating estimates.
The company guides FY18 EPS of $3.32-3.41, excluding non-recurring items, versus a consensus of $3.11.
Amedisys also updates FY18 revenue guidance to $1.63-1.65 billion.

Analysts· Feb 25

BMO Capital Markets upgraded Amedisys to Outperform from Market Perform and lowered the price target to $190.
Credit Suisse and Oppenheimer maintained Amedisys as Outperform but lowered the price target to $195 and $200, respectively.
Analysts at Raymond James, Royal Bank of Canada, and Truist Financial lowered their price targets for Amedisys to $200, $199, and $200, respectively.

Announcements· Aug 7

Amedisys, Inc. (AMED) has reached a settlement with the DOJ regarding a $3.3B merger with UnitedHealth (UNH).
The settlement requires divestitures and a $1.1M fine to resolve the merger challenge.
The agreement may reduce expected synergies and is seen as a catalyst for Amedisys' stock price to make a big comeback.

Generated by AI

Community

Of the messages about AMED, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	4.78%
Newcomers	—	—	—	95.22%

Regulars· Oct 27

Amedisys' stock price fell 15% as Q3 earnings declined and FY22 outlook was cut, with its shares also down 10% after missing Q3 estimates and lowering FY22 guidance.
Analysts have downgraded Amedisys to a Market Perform rating from Outperform, and lowered its price target to $165.00.
Amedisys has issued quarterly earnings results, and its financial results for the three and nine months ended September 30, 2022, were announced in a Form 8-K filing.

Newcomers· Aug 5

Newcomers to the Amedisys stock are focused on its significant price drop, with one user mentioning it's the largest percentage drop since 2011.
Some users are awaiting a buy signal, with one mentioning the use of an "UltraAlgo" to beat the pump and dump game, while another is waiting to see if support will hold on the weekly chart.
Newcomers are also focused on Amedisys' debt situation and its price comparative to book value, with one user noting a debt situation that looks good, but also a high price relative to trend over the last 5 or 10 years.

Generated by AI

Amedisys

Social

Aug 8

Sentiment

Bullish· Jun 9

Bearish· Jul 26

Topics

Earnings· Jul 31

Analysts· Feb 25

Announcements· Aug 7

Community

Regulars· Oct 27

Newcomers· Aug 5

Also Discussed

Amedisys, Inc.

Company Information

Location

Also Discussed

Social

Aug 8

Sentiment

Bullish· Jun 9

Bearish· Jul 26

Topics

Earnings· Jul 31

Analysts· Feb 25

Announcements· Aug 7

Community

Regulars· Oct 27

Newcomers· Aug 5